Cargando…
Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663272/ https://www.ncbi.nlm.nih.gov/pubmed/29104764 http://dx.doi.org/10.1136/esmoopen-2017-000281 |
| _version_ | 1783274792891187200 |
|---|---|
| author | Bakalos, Georgios Schreitmüller, Thomas |
| author_facet | Bakalos, Georgios Schreitmüller, Thomas |
| author_sort | Bakalos, Georgios |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5663272 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56632722017-11-03 Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ Bakalos, Georgios Schreitmüller, Thomas ESMO Open Correspondence BMJ Publishing Group 2017-10-23 /pmc/articles/PMC5663272/ /pubmed/29104764 http://dx.doi.org/10.1136/esmoopen-2017-000281 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | Correspondence Bakalos, Georgios Schreitmüller, Thomas Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title | Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title_full | Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title_fullStr | Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title_full_unstemmed | Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title_short | Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’ |
| title_sort | reply to ‘biosimilars: a position paper of the european society for medical oncology, with particular reference to oncology prescribers’ |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663272/ https://www.ncbi.nlm.nih.gov/pubmed/29104764 http://dx.doi.org/10.1136/esmoopen-2017-000281 |
| work_keys_str_mv | AT bakalosgeorgios replytobiosimilarsapositionpaperoftheeuropeansocietyformedicaloncologywithparticularreferencetooncologyprescribers AT schreitmullerthomas replytobiosimilarsapositionpaperoftheeuropeansocietyformedicaloncologywithparticularreferencetooncologyprescribers |